Quantitative Preferences for Lung Cancer Treatment from the Patients' Perspective: A Systematic Review.

Yasuo SugitaniNaoko SugitaniShunsuke Ono

Published in: The patient (2021)

Our systematic review clarified that patients generally prefer a better efficacy profile to a better safety profile, which underscores the importance of improved benefits in anti-lung cancer drug development.

Keyphrases

systematic review
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
randomized controlled trial
mass spectrometry
high resolution